Martela Corporation publishes an exemption document regarding the share issue, the combination of share series and the application for admission of new shares to trading on a regulated market

Martela has launched a directed share issue targeting approximately €6-8 million, offering up to 17,777,777 new shares at €0.45 each after shareholder approval of the share-series combination and issuance authorization. The subscription window runs from 30 September at 12:00 EEST to 5 October at 10:00 EEST. The equity raise is likely dilutive to existing holders, although it provides additional funding to the company.

Analysis

MARAS faces a near-term technical ceiling at the EUR 0.45 subscription price: investors able to participate have little incentive to buy meaningfully above the placement level until allocation, settlement and free-float dynamics clear. The financing removes some immediate liquidity risk, but the market will focus on the post-money share count and whether the cash merely funds working capital losses rather than a measurable turnaround in order intake, gross margin, or operating cash flow. With the percentage dilution not provided, the exemption document's pro forma capital structure and use-of-proceeds detail are the critical missing inputs.

The second-order concern is that a discounted directed issue can establish a recurring financing template for a thinly traded small-cap, raising the required equity-risk premium even if the balance sheet improves. A fully subscribed book led by credible long-only Nordic investors would soften that signal and could create a tradable post-settlement bounce; weak take-up or rapid secondary selling would instead indicate the company has exchanged solvency runway for persistent multiple compression. The relevant catalyst path is days-to-weeks for subscription results and pricing, then 1-3 months for evidence that new capital converts into improved cash conversion rather than another raise.

Contrarianly, the stock could outperform if the market has already discounted a more punitive rescue financing: an EUR 8m gross raise at a fixed price may be less damaging than feared if it funds a complete working-capital cycle and stabilizes customer confidence. That outcome requires independently verifiable improvement in orders and EBITDA/cash-flow guidance, not management's stated strategic rationale. AKTIA's advisory role is not a material earnings catalyst; any benefit is fee-level and immaterial to the bank's valuation.

Key Decisions for Investors

• Avoid initiating or adding MARAS ahead of subscription close and settlement; use EUR 0.45 as the immediate technical reference, not as a fundamental support level.
• For existing MARAS holders, reduce exposure into any post-announcement liquidity spike unless the final allocation confirms full demand and the exemption document shows a credible cash runway through at least the next 12 months without another equity raise.
• Place a post-settlement watch alert rather than a short recommendation: consider a tactical long only if MARAS holds above EUR 0.45 on sustained volume and management provides quantifiable order, margin, and operating-cash-flow milestones. Exit if the share price breaks the issue price after new shares become tradable or if guidance is cut.
• No actionable AKTIA trade: monitor only for unusually large disclosed underwriting/placement economics, as ordinary advisory fees should not move earnings or valuation.